[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71: 209-249.
|
[2] |
Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer[J]. Annu Rev Pathol, 2022,17:181-204.
|
[3] |
Humphries AD, Streimann IC, Stojanovski D, et al. Dissection of the mitochondrial import and assembly pathway for human Tom40[J]. J Biol Chem, 2005, 280: 11535-11543.
|
[4] |
Namba T. BAP31 regulates mitochondrial function via interaction with Tom40 within ER-mitochondria contact sites[J]. Sci Adv, 2019, 5:eaaw1386. doi: 10.1126/sciadv.aaw1386.
|
[5] |
Burnett JP, Korkaya H, Ouzounova MD, et al. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options[J]. Sci Rep, 2015, 5: 15821. doi: 10.1038/srep15821.
|
[6] |
Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and Limitations: future outlook[J]. Pharmaceutics, 2023,15:1796. doi: 10.3390/pharmaceutics15071796.
|
[7] |
Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer-expanded options, evolving needs[J]. Nat Rev Clin Oncol, 2022, 19: 91-113.
|
[8] |
姜敏,赵玉军.异常上调的CNIH4和TOMM40L基因可能与肝细胞癌预后相关[J].中国普外基础与临床杂志,2022,29: 904-909.
|
[9] |
刘宇.TOMM40L在肝细胞癌中的表达情况及对预后的影响[D].合肥:安徽医科大学,2022:34-36.
|
[10] |
Zhou M, Ye Z, Gu Y, et al. Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling[J]. Int J Clin Exp Pathol,2015,8: 38-52.
|
[11] |
Du Y, Wei N, Ma R, et al. A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer[J]. Cell Death Dis, 2020,11: 731. doi: 10.1038/s41419-020-02952-6.
|
[12] |
Gong Y, Ji P, Yang YS, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets[J]. Cell Metab, 2021,33: 51-64.
|
[13] |
Yang W, Hong L, Guo L, et al. Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer[J]. Cell Discov, 2024,10: 96. doi: 10.1038/s41421-024-00715-7.
|
[14] |
张锦,方瑜,姜伊娜,等. 姜黄素通过调节糖代谢重编程抑制三阴性乳腺癌细胞的恶性表型[J]. 现代中医药, 2023, 43: 109-117.
|